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ABSTRACT
In this prospective hospital-based cohort study that included 43 newly 
diagnosed patients with acute myeloid leukemia, flow cytometric cellular alkaline 
phosphatase (ALP) activity within primitive leukemic cells allowed us to identify 
two groups of patients at diagnosis according to the numbers of leukemic blasts 
expressing ≥ 12% of ALP+ cells (27 patients, Group A) and less than 12% of ALP+ 
cells (16 patients, Group B). Differences in outcome for complete response, relapse 
or treatment resistance, and exitus were statistically analyzed and were significant, 
when comparing the two groups. The overall survival (OS) and event-free survival 
(EFS) differences between Group A and B were statistically significant. The survival 
of Group A patients was significantly shorter than those for Group B. No significant 
relationship was detected in outcome when comparing ELN prognostic-risk group 
based on cytogenetic and molecular profile (patients in the favorable, intermediate, 
and adverse risk groups). Flow cytometric cellular ALP activity at diagnosis may be 
used to estimate relapses and disease persistence more accurately. The limitations 
of our study include the small number of patients enrolled and a short follow-up, 
due to its prospective nature.
INTRODUCTION
Flow cytometry immunophenotyping [1] has 
become one of the mainstream applications for the 
diagnosis and classification of several hematologic 
neoplasms. This technology is indispensable for detection 
of leukemic blasts at a single cell level, clonal lineage 
assignment, identification of aberrant expression of 
antigens, and detection of abnormal rare populations of 
blasts from normal progenitors, with extreme importance 
in tailoring decision-making. Moreover, functional flow 
cytometry testing can effectively provide new insights for 
research and evaluation of disease, and a more complete 
understanding of the complexities and challenges in the 
analysis of leukemic stem cells.
Acute myeloid leukemia (AML) arise from stem 
cells, causing a rapid overproduction of abnormal myeloid 
blasts, usually requiring immediate treatment. AML is not 
a single disease and comprises a heterogeneous group of 
clonal hematopoietic malignancies with poor prognosis, 
being the most common type of acute leukemia in adults 
[2–4]. Patients with AML have high overall mortality 
rate at three years, being higher among patients 65 years 
or older [5]. Current strategies for the treatment of this 
disease, assign prognostically favorable subgroups into 
standard chemotherapy regimens, while unfavorable 
risk patients are generally considered for undergoing 
consolidation with allogeneic stem cell transplantation 
(ASCT).
Alkaline phosphatase (ALP) is expressed at 
very low levels in somatic cells, whereas it is highly 
expressed in primitive stem cells. ALP enzyme has a 
dimeric structure capable of binding Zn2+ and Mg2+ 
ions at different sites to stimulate or inhibit its catalytic 
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reaction. In humans, four forms of ALP cDNA have been 
cloned: one of them is widely distributed (liver, bone, 
kidney) [6, 7], one restricted to the intestine [8], one to the 
placenta [9], and one restricted to teratomas and germ cells 
[10]. ALP hydrolyzes phosphate groups and its activity 
is involved in a broad range of essential physiological 
and pathological processes. Immunohistochemical 
expression of ALP has been reported for embryonal 
carcinoma and teratoma tumors with two different alkaline 
phosphatases localized in stem cell populations, as well 
as in embryonic ectodermal cells [10]. Pluripotent stem 
cells, embryonic stem cells, induced pluripotent stem 
cells and embryonic germ cells express highly elevated 
ALP [11], as demonstrated by western blot, ELISA, 
immunohistochemistry, and highly sensitive fluorescent 
and chemiluminescent substrates [12].
Because stem cells lack specific cell surface markers, 
the identification of this compartment can be difficult, making 
cancer stem cells especially elusive [13]. Thus, we undertook 
a prospective cohort study based on our previous work [14], 
with the objective to investigate whether there might be 
differences in ALP activity within primitive leukemic cells, 
and its association with the potential risk of recurrence and 
mortality in newly diagnosed patients with AML.
RESULTS
Patient characteristics and outcomes
Between May 2015 and May 2018, a total of 106 
patients were diagnosed with acute myeloid leukemia at 
our unit. After exclusion criteria were applied, 43 eligible 
patients were identified and included in the overall analysis. 
The characteristics of patients who were included are shown 
in Supplementary Table 1. The median age of patients was 
67 years (range, 26–91 years). Of these, 20 (46.5%) of 
patients were over 70 years of age, and 23 (53.5%) were 
under 70 years of age. Overall, 30 (69.8%) patients were 
male, and 13 (30.2%) were female (Table 1). Median 
follow-up for OS and EFS was approximately 12 months. 
The 30-month OS and EFS of all AML patients was 21.3% 
and 19% respectively (Figure 1A, 1B). The OS and EFS 
differences for adverse-, intermediate- and favorable-risk 
patients were also compared (Figure 1C, 1D).
Alkaline phosphatase activity differences in 
AML: identification of two patient groups
Differences in ALP+ blast cells at diagnosis were 
analyzed for the entire population. The value of ALP+ 
blast cells was expressed as percentages of the median 
and ranges around the median. Table 1 summarizes 
the median and range of ALP+ blast cells at diagnosis 
according to the age, sex, type of AML (de novo or 
secondary), WHO 2017 classification [15], cytogenetic 
and molecular alterations, European LeukemiaNet (ELN) 
prognostic-risk group based on cytogenetic and molecular 
profile [16], relevant blast immunophenotyping (CD34/
CD117/CD123 backbone), initial treatment, and post-
remission therapy. The diagnostic performance of the ALP 
test as a binary classifier system, or the accuracy of the 
method to discriminate two ALP+ populations, was used 
to determine its predictive value. As shown in Figure 2, 
Receiver Operating Characteristic (ROC) curve analysis 
(area under the curve (AUC) = 0.768, 95% Confidence 
Interval (CI) = 0.596 to 0.94, P-value < 0.0001) allowed 
us to classify two identifiable ALP groups of patients at 
diagnosis according to the numbers of leukemic blasts 
expressing ≥ 12% of ALP+ cells (27 patients in Group A) 
and less than 12% of ALP+ cells (16 patients in Group B).
Differences in outcomes between groups
Overall, 43 patients, with a median age of 63 years 
(range 26–91), had a median value of 18.33% ALP+ 
blast cells (range 0.26–96.93). Twenty-seven patients in 
Group A had a median value of 23.76% of ALP+ blast 
cells ranging from 13.83 to 96.63), and 16 patients in 
Group B had a median value of 4.99% of ALP+ blast 
cells ranging from 0.26 to 11.98 (P-value < 0.0001, 95% 
CI: 15.79 – 24.84).
Differences in outcome comparing the two groups 
were also analyzed. Seven patients in Group A achieved 
a complete response (25.9%), in contrast with 11 patients 
(68.8%) in Group B (P-value = 0.01, 95% CI = 1.34 to 
30.99). Twenty-five patients in Group A relapsed or showed 
treatment resistance (92.6%), whereas this occurred only in 
5 patients (31.3%) in Group B (P-value = <0.0001, 95% 
CI = 0.00 to 0.26). Twenty-two patients in Group A died 
(81.5%), whereas 5 died in Group B (31.3%) (P-value = 
0.002, 95% CI = 0.02 to 0.52). Table 2 summarizes the 
differences between Group A (≥12% ALP+ blasts cells) and 
Group B (<12% ALP+ blasts cells) adjusted for the age, sex, 
type of AML (de novo or secondary), WHO Classification 
of AML (2017 edition), cytogenetic and molecular 
alterations, prognostic-risk group based on cytogenetic 
and molecular profile, relevant blast immunophenotyping 
(CD34/CD117/CD123 backbone), post-remission therapy, 
and outcomes (complete response achievement, relapse or 
treatment resistance, and exitus).
Survival differences between groups
The overall survival (OS) and event-free survival 
(EFS) differences between Group A and B were 
statistically significant. The survival for Group A patients 
was significantly shorter than for Group B. 
The 25-month OS in patients with ≥ 12% of ALP+ 
leukemic cells (Group A) was 9%, and the 10-month EFS 
in the same group was 10%. The 30-month OS and EFS 
in patients with <12% of ALP+ leukemic cells (Group B) 
was 58% and 60% respectively (Figure 3).
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Table 1: Numbers of ALP+ blast cells at diagnosis according to patient characteristics
Patients (n = 43), n (%) APL+ blast cells, median (range), %
Age at diagnosis
<70 years 23 (53.5) 13.83 (1.00 - 96.63)
>70 years 20 (46.5) 19.86 (0.26 - 96.63)
Sex
- Male 30 (69.8) 17.36 (0.26 - 96.63)
- Female 13 (30.2) 20.75 (1.62 - 35.91)
Type of AML
- de novo 30 (69.8) 18.11 (1.20 - 96.63)
- secondary 13 (30.2) 20.75 (1.00 - 95.92)
WHO 2017 classification
- AML with recurrent genetic abnormalities
- AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1 2 (4.7) 49.17 (1.71 - 96.63)
- AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 2 (4.7) 21.81 (13.83 - 29.80)
- AML with mutated NPM1 8 (18.6) 13.85 (1.00 - 24.71)
- AML with biallelic mutations of CEBPA 3 (7.0) 17.09 (6.53 - 21.75)
- AML with myelodysplasia related changes 4 (9.3) 19.19 (9.07 - 95.92)
- Therapy-related AML 1 (2.3) 54.95 (54.95 - 54.95)
- AML not otherwise specified
- AML with minimal differentiation 3 (7.0) 15.49 (8.10 - 20.84)
- AML without maturation 3 (7.0) 22.89 (2.65 - 23.76)
- AML with maturation 8 (18.6) 17.43 (0.26 - 37.77)
- Acute myelomonocytic leukemia 4 (9.3) 29.10 (4.96 - 96.63)
- Acute monoblastic/monocytic leukemia 5 (11.6) 18.33 (1.20 - 26.91)
Cytogenetic alterations
- Normal karyotype 20 (46.5) 13.45 (0.26 - 35.27)
- inv(16)(p13.1;q22) 2 (4.7) 21.81 (13.83 - 29.80)
- Monosomy 7 or del 7q 3 (7.0) 23.76 (15.49 - 54.95)
- Trisomy 8 5 (11.6) 35.91 (26.03 - 96.63)
- t(8;21)(q22;q22.1) 2 (4.7) 49.17 (1.71 - 96.63)
- t(11q23) 1 (2.3) 2.65 (2.65 - 2.65)
- Complex karyotype 3 (7.0) 9.53 (4.96 - 20.84)
- Others 7 (16.3) 20.75 (8.10 - 95.92)
Molecular alterations
- NPM1 mutated without FLT3-ITD 5 (11.6) 5.35 (1.00 - 17.89)
- FLT3-ITD with or without NPM1 mutated 5 (11.6) 18.97 (1.20 - 26.03)
- FLT3-TKD 1 (2.3) 29.8 (29.8 - 29.8)
- CEBPA mutated 3 (7.0) 17.09 (6.53 - 21.75)
- c-Kit mutated 1 (2.3) 13.83 (13.83 - 13.83)
- Wild type 28 (65.1) 21.56 (0.26 - 96.63)
Cytogenetic and molecular prognostic-risk group
- Favorable 13 (30.2) 13.83 (1.00 - 96.63)
- Intermediate 23 (53.5) 22.89 (0.26 - 96.63)
- Adverse 7 (16.3) 9.53 (1.62 - 26.03)
Relevant LSC markers
- CD34+/CD123+/CD117+ 28 (65.1) 20.79 (0.26 - 96.63)
- CD34+/CD123-/CD117+ 3 (7.0) 95.92 (2.65 - 96.63)
- CD34-/CD123+/CD117+ 9 (20.9) 9.82 (1.00 - 30.39)
- CD34-/CD123+/CD117- 3 (7.0) 18.33 (11.98 - 26.91)
Initial treatment
- CETLAM12<70* 20 (46.5) 11.82 (1.00 - 96.63)
- CETLAM12>70† 5 (11.6) 15.49 (0.26 - 35.27)
- FLUGAZA clinical assay‡ 11 (25.6) 21.75 (17.64 - 96.63)
- Others§ 7 (16.3) 11.98 (1.62 - 30.39)
Post remission therapy
- Allogeneic SCT 12 (28.0) 23.02 (1.00 - 96.63)
- Other 31 (72.0) 17.89 (0.26 - 96.63)
Abbreviations: APL, alkaline phosphatase; AML, acute myeloid leukemia; WHO, world health organization; NPM1, nucleophosmin 1; FLT3-ITD, fms-like tyrosine kinase 3 
internal tandem duplication; FLT3-TKD, fms-like tyrosine kinase 3 tyrosine kinase domain; SCT, stem cell transplant.
*Cytarabine + idarubicin; †Cytarabine + fludarabine; ‡Cytarabine + fludarabine / Azacitidine; §Azacitidine / Decitabine / Cytarabine + idarubicin + quizatinib or placebo / None.
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Multivariable analysis
Univariate and multivariate Cox proportional 
hazards models were used to identify factors that are 
associated with OS and EFS in patients with AML 
(Table 3). ALP expression was a significant predictor of 
OS on univariate (hazard ratio [HR] = 0.32, 95% CI = 
0.11 to 0.87, P-value < 0.025) analysis. ALP expression 
was a significant predictor of EFS on univariate ([HR] 
= 0.19, 95% CI = 0.17 to 0.52, P-value = 0.0012) and 
multivariate ([HR] = 0.25, 95% CI = 0.09 to 0.70, P-value 
< 0.0079) analyses. In the univariate Cox model for OS, 
age, favorable and intermediate risk, AML type, and 
ALP Group were associated with a significant impact on 
survival. The only factor that retained their significance 
on multivariate analysis was age. In the univariate Cox 
model for EFS, age, favorable and intermediate risk, and 
ALP Group were associated with a significant impact on 
progression/relapse. The only factors that retained their 
significance on multivariate analysis were favorable risk 
and ALP group.
DISCUSSION
Acute myeloid leukemia is a heterogeneous clonal 
disorder associated with a relatively high early mortality 
rate and poor overall chances for recovery. Even with 
current treatments, the relative 5-year survival rate for 
patients with AML is only 5% after the age of 65 [17]. 
Current diagnosis and medical treatment of AML is 
expensive, not just in terms of cost, but also in terms of 
the impact on prolonged overall treatment duration for 
Figure 1: Plots of Kaplan-Meier limit estimates of overall survival and event-free survival curve analysis of acute 
myeloid leukemia patients at diagnosis. Plots of Kaplan-Meier limit estimates of overall and event-free survival of acute myeloid 
leukemia ungrouped and grouped patients according to the risk. Plots of Kaplan-Meier limit estimates of overall and event-free survival of 
acute myeloid leukemia ungrouped patients are shown in (A and B) respectively. Overall and event-free survival differences for adverse-, 
intermediate- and favorable-risk patients (A, I, and F) are shown in (C and D) respectively.
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patients and their families. Despite new therapy options 
having been developed to treat AML, advancement in 
understanding the pathogenesis of AML is continuously 
needed. Furthermore, the capability to accurately predict 
survival is often difficult, raising the need for new 
predictive biomarkers in AML therapeutics.
The fundamental goal of personalized medicine, 
aimed at providing patient-specific molecular insights, 
combines genomic, clinical, and other types of data, to 
provide strategies aimed at treatment optimization based on 
individual patient characteristics. In recent years, advances 
in genotypic arrays, digital PCR, and next-generation 
sequencing, also known as high-throughput sequencing, 
have played a key role in developing new assays, such as 
those for predicting AML relapse after ASCT, for mutational 
screening, risk stratification, guided therapy, or Measurable 
residual disease (MRD) monitoring. Multiparameter flow 
cytometry in the clinical laboratory has also become an 
essential technology to increase the sensitivity of leukemia 
detection at the single cell level, especially for identifying 
very low levels of residual disease immediately after 
treatment and during follow-up.
Assessment of MRD is today considered 
indispensable for forecasting the significance and 
association with treatment outcome and survival [18]. 
However, the sensitivity of the assays, phenotypic shifts 
at relapse, low frequency of residual leukemic stem cells, 
quality of the marrow aspirate, or the use of peripheral 
blood, may lead to identifying false-positive and false-
negative patient groups by current approaches [19]. 
AML comprises a dynamic disease with a very complex 
landscape of aberrant phenotypic, cytogenetic and 
molecular genetic abnormalities, that importantly confer 
independent biological properties of the leukemic cells.
In 1970, Clarkson et al. found leukemic cells to 
behave as a self-maintaining population [20]. Although 
their data did not preclude some influx of leukemic “stem 
cells” from an unrecognized precursor compartment, they 
found no evidence to support this hypothesis. On the same 
subject of AML, Bonnet and Dick (1997), demonstrated that 
leukemic cells obtained from patients possess differentiative 
and proliferative capacities, as well as the self-renewal 
properties found in leukemic stem cells [21]. However, the 
heterogeneity of the stem cell compartment supports that 
the stem cell concept is not necessarily associated with a 
specific cellular entity, but rather a function that can be 
assumed by numerous diverse cell types. As a result, the 
cancer stem cell concept cannot be universally applicable, 
based on complex evolution, phenotypic heterogeneity and 
therapeutic challenges of many human cancers, making 
Figure 2: Receiver operating characteristic (ROC) curves. According to ROC curve analysis, 12% of ALP+ was confirmed as 
the cut-off point of ALP+ leukemic cell counting for survival outcome of AML patients. ROC curve analysis (area under the curve = 0.768, 
95% CI = 0.596 to 0.94,  P-value < 0.0001) classified two identifiable ALP groups of patients at diagnosis according to the numbers of 
leukemic blasts expressing ≥ 12% of ALP+ cells (27 patients in Group A) and less than 12% of ALP+ cells (16 patients in Group B).
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difficult the identification of rare molecular and phenotypic-
based putative leukemic stem cells [22, 23].
Aside from antigen expression properties on AML 
bulk cells, and that antigen coexpression on leukemic 
stem cells (LSC) makes it difficult to specifically target 
this compartment, LSCs have unique features based on 
metabolic response to drugs, cell stress control, and other 
key aspects of stemness and chemotherapy resistance. 
Based on the clonal nature of tumors, and after the 
demonstration that leukemic stem cells from patients 
Table 2: Differences between Group A and Group B regarding total number of ALP+ blast cells at 
diagnosis
Overall (n = 43) Group A (n = 27) Group B (n = 16) P-value (95% CI)
ALP+ blast cells, median (range), % 18.33 (0.26 - 96.63) 23.76 (13.83 - 96.63) 4.99 (0.26 - 11.98) <0.0001 (15.79 - 24.84)****
Age at diagnosis, median (range), years 63.0 (26 - 91) 73.0 (26 - 81) 59.5 (31 - 91) 0.38 (-5.00 - 17.00)
Sex, n (%)
- Male 30 (69.8) 17 (63.0) 13 (81.3)
0.31 (0.50 - 16.99)
- Female 13 (30.2) 10 (37.0) 3 (18.7)
Type of AML, n (%)
- de novo 30 (69.8) 19 (70.4) 11  (68.8%)
1 (0.22 - 4.93)
- secondary 13 (30.2) 8 (29.6) 5 (31.2%)
WHO 2017 classification, n (%)
- AML with recurrent genetic abnormalities 15 (34.9) 9 (33.3) 6 (37.5) 1 (0.27 - 5.18)
- AML with myelodysplasia related changes 4 (9.3) 3 (11.1) 1 (6.3) 1 (0.00 - 7.47)
- Therapy-related AML 1 (2.3) 1 (3.7) 0 (0.0) 1 (0.00 - 65.75)
- AML not otherwise specified 23 (53.5) 14 (51.9) 9 (56.2) 1 (0.29 - 4.99)
Molecular alterations, n (%)
- NPM1 mutated without FLT3-ITD 5 (11.6) 1 (3.7) 4 (25.0) 0.06 (0.71 - 441.52)
- FLT3-ITD with or without NPM1 mutated 5 (11.6) 3 (11.1) 2 (12.5) 1 (0.09 - 11.26)
- NPM1 and FLT3 wild type 33 (76.8) 23 (85.2) 10 (62.5) 0.14 (0.05 - 1.58)
Cytogenetic and molecular prognostic-risk 
group, n (%)
- Favorable 13 (30.2) 7 (25.9) 6 (37.5) 0.50 (0.36 - 7.82)
- Intermediate 23 (53.5) 17 (63.0) 6 (37.5) 0.12 (0.08 - 1.50)
- Adverse 7 (16.3) 3 (11.1) 4 (25.0) 0.39 (0.37 - 20.75)
Blasts at diagnosis, median (range), % 45.0 (6.0 - 98.0) 50.0 (18.0 - 98.0) 39.0 (6.0 - 88.8) 0.35 (-7.99 - 23.00)
WBC at diagnosis, median (range), n × 109/L 8.5 (0.5 - 249.1) 5.9 (0.7 - 249.1) 13.3 (0.5 - 65.4) 0.93 (-10.80 - 6.60)
Relevant LSC markers, n (%)
- CD34+/CD123+/CD117+ 28 (65.1) 19 (70.0) 9 (56.2) 0.51 (0.12 - 2.39)
- CD34+/CD123-/CD117+ 3 (7.0) 2 (7.5) 1 (6.3) 1 (0.01 - 17.38)
- CD34-/CD123+/CD117+ 9 (20.9) 4 (15.0) 5 (31.2) 0.26 (0.45 - 15.67)
- CD34-/CD123+/CD117- 3 (7.0) 2 (7.5) 1 (6.3) 1 (0.01 - 17.38)
Post remission therapy, n (%)
- Allogeneic SCT 12 (28.0) 8 (30.0) 4 (25.0)
1.0000 (0.26 - 7.00)
- Other 31 (72.0) 19 (70.0) 12 (75.0)
Outcomes, n (%)
- Complete response 18 (41.9) 7 (25.9) 11 (68.8) 0.01 (1.34 - 30.99)*
- Relapse or Treatment resistance 30 (69.8) 25 (92.6) 5 (31.3) <0.0001 (0.00 - 0.26)****
- Exitus 27 (62.8) 22 (81.5) 5 (31.3) 0.002 (0.02 - 0.52)**
Abbreviations: CI, confidence interval; ALP, alkaline phosphatase; n, number; AML, acute myeloid leukemia; WHO, world health organization; NPM1, 
nucleophosmin 1; FLT3-ITD, fms-like tyrosine kinase 3 internal tandem duplication; WBC, white blood cells; L, liter; LSC, leukemic stem cell; SCT, stem 
cell transplant.
*p-value < 0.05; **p-value <0.01; ****p-value <0.0001.
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with AML reconstitute the full spectrum of phenotypes 
in the malignant populations that they regenerate in 
transplanted mice, we hypothesized that ALP could help 
to identify primitive leukemic cells [14]. Moreover, it has 
been demonstrated that ALP activity may be useful for 
the diagnosis of acute myelomonocytic and monocytic 
leukemia in dogs [24]. In parallel with flow cytometric 
immunophenotyping, Stokol et al. used a cytochemical 
staining approach for ALP activity, concluding that ALP 
activity in canine AML can be especially helpful when 
flow cytometric results are inconclusive. We then decided 
to implement a new ALP flow cytometric method test, 
using a novel fluorogenic live cell permeant substrate for 
ALP [12], since this stain efficiently visualized pluripotent 
stem cells such as human embryonal carcinoma, murine 
and human embryonic stem cells and induced pluripotent 
stem cells under fluorescent microscopy [25]. Our 
method uses a no-lyse no-wash approach, offering 
opportunities to combine live cell response and functional 
assessment in combination with cell immunophenotyping 
(Supplementary Figure 1), while minimizing sample 
preparation effects on the cell biology as the primary 
Figure 3: Plots of Kaplan-Meier limit estimates of overall survival and event-free survival curve analysis of acute 
myeloid leukemia patients, according to the numbers of alkaline phosphatase (ALP) positive leukemic cells at diagnosis. 
Overall survival after diagnosis was compared between high ALP Group (A) and low ALP Group (B). Patients with ALP+ leukemic cells ≥ 
12% achieved shorter OS than those with ALP+ leukemic cells < 12%. According to ROC curve analysis, 12% of ALP+ was confirmed as 
the cut-off point of ALP+ leukemic cell counting for survival outcome of AML patients. Kaplan-Meier plots of overall survival for grouped 
acute myeloid leukemia patients are shown in (A). Plots of Kaplan-Meier product limit estimates of event-free survival of grouped patients 
according to the numbers of ALP positive leukemic cells at diagnosis are shown in (B).
Table 3: Multivariate analyses
Variable

















Age 1.10 (1.00 – 1.10) 0.0014** 1.04 (1.00 – 1.08) 0.0341* 1.00 (1.00 –1.10) 0.039* 1.01 (0.99 – 1.05) 0.21
Sex 1.40 (0.56 – 3.40) 0.48 0.58 (0.24 – 1.92) 0.47 1.00 (0.45 – 2.20) 1.00 - -
ALP Group 0.32 (0.11 – 0.87) 0.025* 0.47 (0.15 – 1.34) 0.15 0.19 (0.07 – 0.52) 0.0012** 0.25 (0.09 – 0.70) 0.0079**
AML Type 4.20 (1.80 – 9.80) 0.0009*** 1.50 (0.49 – 5.27) 0.43 1.60 (0.71 – 3.50) 0.27 0.48 (0.16 – 1.46) 0.20
Favorable Risk 0.25 (0.09 – 0.70) 0.0086** 0.33 (0.07 – 1.69) 0.18 0.24 (0.09 – 0.61) 0.0026** 0.23 (0.06 – 0.93) 0.039*
Intermediate 
Risk 2.70 (1.00 – 5.80) 0.042
* 0.78 (0.19 – 3.11) 0.72 3.10 (1.40 – 6.80) 0.0053** 1.01 (0.33 – 3.12) 0.99
Adverse Risk 1.60 (0.44 – 5.70) 0.50 - - 1.20 (0.41 – 3.60) 0.72 - -
% Blasts 0.99 (0.97 – 1.00) 0.20 1.00 (0.98 – 1.03) 0.76 1.00 (0.98 – 1.00) 0.99 - -
WBC 0.99 (0.98 – 1.00) 0.46 1.00 (0.99 – 1.01) 0.94 1.00 (0.99 – 1.00) 0.64 - -
Abbreviations: CI, confidence interval; ALP, alkaline phosphatase; AML, acute myeloid leukemia; WBC, white blood cells.
*p-value < 0.05; **p-value < 0.01; ***p-value < 0.001.
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goal [26]. This method can also be used to identify rare 
cells [27]. Additionally, assays dealing with live kinetic 
analysis, like calcium flux and enzyme rate, or assays that 
depend on continued active drug transport just prior to 
analysis, like side population analysis must be done with 
live cells, preferably with as little sample manipulation as 
possible. Recent work by the authors [14] showed elevated 
ALP activity in CD34+ cells in highly refractory cancers. 
This study was made possible by using this new non-toxic 
cell-permeant fluorescent ALP for live cells without need 
to add multidrug resistant transporter inhibitors, taking 
advantage of one of the most-widely used enzyme-based 
standards, known as the aldehyde dehydrogenase (ALDH) 
assay [28]. Previously, we demonstrated measurement of 
ALP activity with ABCG2 efflux pump activity using this 
reagent in combination with side population analysis, 
making its use feasible for primitive stem cells expressing 
ABC transporters. This can only be done with live healthy 
cells at the point of analysis [14].
Measuring live cell response function and 
immunophenotype with the minimum possible sample 
manipulation, may increase the potential for discovery 
of clinically relevant cell subsets. This area of research 
is particularly interesting from a both theoretical and 
practical point of view. As far as we know, some 
phenotypic characteristics may relate to clinical outcome 
in AML patients, i.e, CD34 negativity related with NPM1 
mutation, CD56 expression in AML with (8;21), or CD2, 
CD36, CD11b or CD56 positivity in other types of AML. 
However, attempts to characterize these associations 
have yielded inconclusive results. Given we lack specific 
markers to identify if a given phenotype is tightly linked 
or specifically caused by some mutations, maybe the only 
way to identify rare cell types is by combining phenotype 
information with and functional assays.
At the light of our results, increased cellular ALP 
activity in AML with no evidence of aberrant antigen 
expression is still unclear and should be confirmed in a 
large series of patients. Importantly in the low residual 
disease, MRD evaluation by whatever the method 
(leukemia-associated immunophenotypes (LAIPs) 
identification vs. “different from normal” approaches) 
has the value of indicating the clinicians “how things 
are going”, and that it may have a definitive underlying 
functional importance is to achieve and maintain a low or 
negative value for ALP activity, because a marked increase 
in this biomarker could be interpreted to reflect increased 
pathological functional activity in a not yet detected 
leukemic but previously fully identified population, the 
emergence of a new and probably more immature and 
aggressive type of cells that may in fact determine the 
clinical course of the patient, or to provide some clues 
for more proliferative advantages related to a given 
phenotype.
In this work, we have shown and validated that 
ALP expression by blast cells at diagnosis may have a 
significant impact to identify two different groups of 
patients. In addition, we have demonstrated that ALP also 
has a significant impact to predict complete response, 
relapse or treatment resistance, and exitus, independently 
of variables such as age, sex, type of AML (de novo or 
secondary), WHO Classification of AML (2017 edition), 
cytogenetic and molecular alterations, ELN prognostic-
risk group based on cytogenetic and molecular profile, 
relevant blast immunophenotyping (CD34/CD117/CD123 
backbone), initial treatment, and post-remission therapy 
(Table 2).
Despite the cohort’s small number, some risk factors 
correlated with overall survival and event free survival. 
Specifically, age entered all univariate and multivariate 
models except with the EFS in the multivariate, and 
favorable risk only did not correlated well with OS in the 
multivariate. Intermediate risk correlated well with OS 
and EFS in the univariate. Finally, the ALP group was 
significant in the univariate model for EFS and OS, as well 
as in the multivariate model for EFS. The ALP group only 
did not correlate with OS in the multivariate (Table 3).
Surprisingly, the percentage of ALP+ blast cells 
in the intermediate risk group (median: 22.89, range: 
0.26–96.63) was higher than that of the adverse risk group 
(median: 9.53; range: 1.62–26.03), suggesting that the 
intermediate risk group may include a relative number 
of patients with adverse risk (Table 1). Despite that, 
this result can also be limited by the bias of the cohort’s 
small number, this observation is supported by the OS 
and EFS Kaplan-Meier analyses according to favorable, 
intermediate, and adverse definitions (Figure 1C and 1D). 
Even with these limitations, our results have significant 
clinical and scientifically important implications.
The outcome of AML treatment is highly variable 
and still not individually predictable [29]. Currently, the 
most refined predictive data that relate to the prognosis 
of AML are those derived of cytogenetic and molecular 
analysis. However, other most determinant predictive 
factors may exist, and that they may reflect the degree of 
immaturity of the main burden of cells that proliferate in 
a given case of AML, and that this degree of immaturity 
(as judged by a functional analysis) is more prognostically 
determinant that the cytogenetic or molecular 
characteristics of leukemic cells. However, this is only a 
hypothesis to verify, and, in fact, we have no explanation 
for the apparently contradictory result of the lack of 
correlation of ALP and cytogenetics. Relative to other 
cancers, AML has a comparatively low level of genetic 
heterogeneity, suggesting that epigenetic heterogeneity 
is of primary importance. Thus, epigenetic factors such 
as DNA methylation, genomic imprinting, histone 
modifications, and expression control by noncoding RNA, 
may also play an important role. If confirmed in larger 
series of patients, our results open a new perspective of 
research in the analysis of outcome in AML. Moreover, 
if cellular alkaline phosphatase activity is a prognosticator 
Oncotarget6977www.oncotarget.com
at diagnosis, it could help to investigate how to reach the 
ultimate goal of individualized risk assessment as a guide 
for therapy decision-making, or to design new novel 
treatment targets in AML. The development of novel ALP 
inhibitors and modulators [30] for the treatment of AML 
are promising approaches to reduce the increased mortality 
associated with this heterogeneous disease characterized 
by a multitude of molecular abnormalities. Since several 
methods are only applicable for MRD detection on a 
clinical routine basis, cellular ALP could help to better 
classify or to predict the behavior of the disease, as well 
as to is really predicting the outcome in a given patient. 
Furthermore, it would be also very interesting to study the 
comparative value of monitoring MRD regularly with flow 
cytometric ALP, as truly negative non-detectable MRD 
status has strong clinical relevance in AML, making it an 
essential tool in the overall strategy adopted to treat AML.
The limitations of our study include the small 
number of patients enrolled and a short follow-up, due to 
its prospective nature. We are fully aware that standard risk 
assessment markers have been well validated in numerous 
large studies and suggest that findings in this small set 
of 43 patients may not be valid in a larger population. 
Despite this small number, this study offers evidence 
to the hypothesis that intrinsic cellular ALP activity at 
diagnosis may be used to estimate relapses and disease 
persistence more accurately. Larger studies will be needed 
to determine whether ALP activity in primitive leukemic 
cells is associated with the potential risk of recurrence and 
mortality in newly diagnosed patients with AML.
Since the discovery of the hybridoma technology, 
many monoclonal antibodies have been available for 
laboratory studies, making possible to dissect human 
malignancy. In the next few years, more investigations 
should shed light on the translational utility of new 
available biological indicators aimed at detecting cell 
function, and discovering in combination with flow 
cytometry immunophenotyping, the complex and 
heterogeneous biology of the stem cell compartment in 
human pathology.
MATERIALS AND METHODS
Study design and patient population
This was a prospective cohort study of patients 
newly diagnosed with acute myeloid leukemia and 
completed follow-up. From May 2015 through May 
2018, 106 patients were diagnosed with AML at the 
hematological cytometry unit at Germans Trias i Pujol 
Hospital (HGTiP) in Badalona (Spain) that covers an area 
of approximately 700,000 inhabitants. After applying 
the exclusion criteria, 43 patients (male 30, female 13; 
median age 63 years, range 26–91) were included in our 
study. Most of the patients were initially treated according 
to the Spanish CETLAM protocols, based on the use of 
idarubicin or fludarabine with cytarabine. A total of 12 out 
of 43 patients underwent allogeneic stem cell transplant 
(ASCT) following chemotherapy. The patient’s risk 
(favorable, intermediate, adverse) was evaluated according 
to ELN 2017 recommendations, based on cytogenetic 
and/or molecular abnormalities [16]. Details of patient 
population and statistics are provided in Table 1 and Table 
2 respectively. All patients enrolled in this study provided 
Figure 4: Representative flow cytometric study of the alkaline phosphatase activity in a patient of the ALP ≥ 12% 
group. Alkaline phosphatase positive cells are represented in combination with CD34 staining at diagnosis (upper row) and after relapse 
(lower row). Reference contour plots for two bone marrow aspirates are compared in the same patient, displaying high levels of alkaline 
phosphatase activity in combination with CD34 staining. The statistics in the region represents percentage of the gate.
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their informed consent in accordance with the Declaration 
of Helsinki. All procedures were in accordance with 
the internal  protocols of our laboratory, which were 
authorized by the HGTiP Clinical Investigation Ethical 
Committee, in agreement with current Spanish legislation.
Flow cytometry methods
All EDTA-anticoagulated bone marrow (n = 38) 
and blood (n = 5) samples were prepared using a modified 
previously developed method [27] aimed at avoiding 
the lysis of erythrocytes during sample preparation, 
which can result in unwanted damage to leukocytes, 
and conceivably to leukemic cells. As most enzyme 
functions are performed at 37°C, we first established 
an optimal Alkaline Phosphatase Live Stain (APLS, 
Thermo Fisher Scientific) stable loading time (t = 20 min) 
and temperature (T = 37°C) to measure ALP enzymatic 
activity [14]. This dye is a cell-permeable fluorescent 
substrate for ALP that is non-toxic to cells. Importantly, 
ammonium chloride- and paraformaldehyde-based lysing 
solutions impair and almost completely abrogate ALP 
staining, are not recommended for detection of ALP+ cells 
(Supplementary Figure 1). The KG-1a cell line, derived 
from Human Caucasian bone marrow acute myelogenous 
leukemia [31], was used as a positive control for highly 
expressing ALP+ cells (Supplementary Figure 2).
Briefly, our staining strategy used Vybrant™ 
DyeCycle™ Violet stain (DCV, Thermo Fisher Scientific), 
a low cytotoxicity permeable DNA-specific dye that can 
be used for DNA content cell cycle and stem cell Side 
Population analysis by flow cytometry [32]. DCV can be 
excited with violet 405 nm laser light and can be used for 
simultaneous measurement with APLS, which is excited 
with blue 488 nm laser light and its emission can be 
collected using a standard FITC filter (for example 530/30 
nm). Subsequently, cells were stained with fluorophore-
conjugated monoclonal antibodies for 20 min at room 
temperature as recommended by the manufacturer (PE-
CD123, PECy5-CD34 and PECy7-CD117, Sysmex 
GmbH). The improved phycoerythrin (PE) signal using 
561 nm excitation together with the fact that there is 
no need for color compensation between FITC and 
PE under 488 nm and 561 nm excitation, results in the 
improved immunophenotypic analysis of leukemic cells 
by multicolor flow cytometry [33].
Stained cells were diluted with Hank’s Balanced 
Salt Solution (HBSS) (1000 µL final volume) prior to 
sample acquisition. All cell measurements were done 
using the Attune™ Acoustic Focusing Cytometer and the 
Attune™ NxT Acoustic Focusing Cytometer (Thermo 
Fisher). Samples were acquired at 25–100 µL/min sample 
rates, and a minimum of 100,000 DCV+ events were 
collected per sample when possible. Threshold levels 
were set empirically using a Violet-Side Scatter (SSC) vs. 
DCV-H dual parameter plot to eliminate debris and the 
large numbers of red blood cells that are found in unlysed 
blood or bone marrow from detection. DCV was excited at 
405 nm and its emission was collected using the following 
filter combination: 413 LP, 495 DLP, and 440/50 BP in the 
VL2 detector.
SSC was detected using the violet laser 405 nm with 
a 405/10 nm bandpass filter. APLS was detected with the 
blue laser 488 nm excitation and a 530/30 nm bandpass 
filter in the BL1 (Blue Laser) detector. For the Attune™ 
NxT upgraded with the yellow laser kit, PE was excited at 
561 nm and its emission was collected using the following 
filter combination: 595 LP, 600 DLP, and 585/16 BP in the 
YL1 detector. PECy5 was detected with the yellow laser 
561 nm excitation and a 695/40 nm bandpass filter in the 
YL3 detector. PECy7 was detected with the yellow laser 561 
nm excitation and a 780/60 nm bandpass filter in the YL4 
detector. APLS, PE, PECy5, PECy7 and DCV fluorescence 
are displayed on a logarithmic scale. Representative contour 
plot analysis for two bone marrow aspirates at diagnosis and 
relapse, used to calculate ALP+ cell numbers in combination 
with CD34 staining is shown in Figure 4.
ALP+ cell numbers were determined in parallel to 
flow cytometry immunophenotyping of leukemia cells 
performed at the HGTiP clinical hematology laboratory. 
Standard immunophenotyping was performed on a 
FC500 (Beckman Coulter) flow cytometer until October 
2016, and on a Navios™ flow cytometer (Beckman 
Coulter) from this date onwards. Blast cells were 
identified using cell surface protein markers according 
to the ELN recommendations [16]. MPO/CD45/CD34/
CD117/CD123/Myeloid/T-Lymphoid/B-lymphoid and 
megakaryocyte (MK) markers were used for typifying 
the blastic population through the identification of 
LAIPs (whenever possible), or through the detection 
of abnormalities in the different-from-normal cellular 
distribution in association with a low expression of CD45 
and low SSC. A minimum of 20,000 events were studied at 
diagnosis. A marker was considered as positive when was 
expressed by ≥20% of blastic cells. Assessment of MRD 
was performed on bone marrow aspirates with a minimum 
sensitivity of 0.1%. LAIPs identified at diagnosis were 
carefully looked for, and shifts in the relative scatter 
distribution of the different-from-normal pattern were also 
taken into account.
Statistical methods
We used receiver operating characteristic (ROC) 
analysis, area under the curve (AUC), sensitivity and 
specificity to measure prognostic accuracy of our test in 
predicting EFS. The optimal cut-off value was identified 
according to the Youden’s Index to classify patients into 
two groups [34]. Differences between categorical variables 
in each group were compared using two-sided Fisher’s 
exact tests. Differences between continuous variables in 
each group were compared using two-sided Wilcoxon 
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rank sum tests. EFS and OS rates were estimated by the 
method described by Kaplan and Meier [35]. EFS was 
defined as the time from diagnosis until progression, 
death, or the last follow-up date. OS was defined as the 
time from diagnosis until death or the last follow-up date. 
Patients that underwent ASCT were censored. Differences 
in survival between each group were tested for statistical 
significance using the two-sided log-rank test with the 
Bonferroni method to adjust P value. Univariate analysis 
using the Cox proportional hazards model was performed 
to investigate the impact of % ALP at diagnosis on EFS 
and OS, adjusting for the following variables: age, sex, 
ELN prognostic-risk group, blast percentage, white blood 
cell (WBC) count and AML type (de novo vs, secondary). 
Factors prognostic for EFS and OS with a P-value < 0.5 
in the univariate analysis were studied in a multivariate 
analysis. A P-value < 0.05 was considered statistically 
significant. R Studio version 1.1.463 (https://www.R-
project.org/) was used for all statistical analysis.
CONCLUSIONS
In this study we have found that increased cellular 
alkaline phosphatase activity in leukemic cells at diagnosis 
was significantly associated with a higher risk of relapse, 
or treatment resistance, and mortality. Due to the small 
number of patients enrolled in this study, this finding 
requires further investigation.
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